Invion Ltd
ASX:IVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E.ON SE
XETRA:EOAN
|
DE |
|
Laster Tech Co Ltd
TWSE:3346
|
TW |
|
P
|
Pan Electronics India Ltd
BSE:517397
|
IN |
Invion Ltd
Research & Development
Invion Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Invion Ltd
ASX:IVX
|
Research & Development
-AU$1.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$36.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Invion Ltd
Glance View
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.
See Also
What is Invion Ltd's Research & Development?
Research & Development
-1.3m
AUD
Based on the financial report for Jun 30, 2025, Invion Ltd's Research & Development amounts to -1.3m AUD.
What is Invion Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
18%
Over the last year, the Research & Development growth was 52%. The average annual Research & Development growth rates for Invion Ltd have been 18% over the past three years , 4% over the past five years , and 18% over the past ten years .
